Company Filing History:
Years Active: 2006-2009
Title: Alan Collis - Innovator in Pharmaceutical Chemistry
Introduction
Alan Collis is a notable inventor based in Basking Ridge, NJ (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that serve as tumor necrosis factor (TNF) inhibitors. His work has implications for treating diseases related to elevated TNF levels.
Latest Patents
Alan Collis holds 2 patents that focus on innovative chemical compounds. His latest patents include "Heteroaryl-cyclic acetals," which describe compounds that are useful as pharmaceuticals. These compounds feature a complex structure that includes various heteroaromatic rings and are designed to inhibit TNF. Another significant patent is for "Imidazolyl-cyclic acetals," which also serves as TNF inhibitors, showcasing his expertise in creating therapeutic agents.
Career Highlights
Collis is currently employed at Aventis Pharma Limited, where he continues to advance his research in pharmaceutical development. His work has been instrumental in creating new treatments that address critical health issues.
Collaborations
Throughout his career, Alan has collaborated with notable colleagues, including Frank Halley and Iain M McLay. These partnerships have contributed to the success of his research and the development of innovative pharmaceutical solutions.
Conclusion
Alan Collis is a distinguished inventor whose work in pharmaceutical chemistry has led to the development of important TNF inhibitors. His contributions continue to impact the field and improve treatment options for various diseases.